Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Organogenesis Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Organogenesis Holdings's regulatory disclosures and financial reporting.
Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards. The filing notes that some positions represent restricted stock units granted under the 2018 Equity Incentive Plan, with unvested RSUs scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029.
Organogenesis Holdings Inc. provides an in‑depth look at its regenerative medicine business, focused on advanced wound care and surgical and sports medicine products like Apligraf, Dermagraft, PuraPly, NuShield, Affinity, Novachor and ReNu.
The company outlines major shifts in Medicare and CMS policy for skin substitutes, including new 2026 payment structures and the WISeR prior‑authorization model, which are already contributing to a significant year‑over‑year revenue decline in early 2026 and may pressure future utilization and profitability.
Organogenesis also highlights mixed but generally supportive Phase 3 data for its ReNu osteoarthritis program and the start of a rolling BLA, plus a long‑term lease for a new Smithfield, Rhode Island biomanufacturing facility intended to bring Dermagraft production back online and expand capacity from 2027.
Organogenesis Holdings Inc. reported record results for 2025, driven by strong growth in advanced wound care. Net product revenue for the year reached $563.0 million, up 17% from 2024, with advanced wound care contributing $531.2 million. Net income improved to $37.0 million from $0.9 million, and Adjusted EBITDA nearly doubled to $98.1 million.
In the fourth quarter of 2025, net product revenue rose 78% to $225.1 million, and net income jumped to $43.7 million. Gross margin remained strong at 76% for the year. The company ended 2025 with $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations.
For 2026, management expects total net revenue between $350.0 million and $420.0 million, a decline of 25% to 38% from total net revenue of $564.2 million in 2025. The company anticipates a sharp revenue drop in early 2026 due to CMS reimbursement and coverage changes for skin substitutes, followed by stronger quarter-over-quarter growth later in the year and a return to more “normalized” growth in 2027.
Organogenesis Holdings Inc. has appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective February 18, 2026. His annual base salary was increased to $345,000, with no other changes to his compensation.
McGuire previously served as the company’s Vice President, Corporate Controller since September 2023 and earlier was Corporate Controller at Cynosure, LLC and a director at PricewaterhouseCoopers LLP. There are no family relationships or related-party transactions requiring disclosure. Concurrently, David Francisco ceased serving as principal accounting officer but continues as Chief Financial Officer and principal financial officer.
Organogenesis Holdings Inc. executive Lori Freedman, Chief Administrative and Legal Officer, reported multiple equity awards. She received a stock option for 115,812 shares at $0 per share, vesting in equal annual installments over four years beginning February 15, 2026. She was also granted 203,125 restricted stock units under the 2018 Equity Incentive Plan, each convertible into one share of Class A common stock, vesting annually over four years from the same date. In addition, 42,780 shares of Class A common stock were issued upon vesting and settlement of a 2025 performance share award. A separate disposition of 14,267 shares at $3.84 per share was reported to cover tax obligations by delivering shares, leaving her with 1,023,355 Class A shares directly owned after these transactions.
Organogenesis Holdings Inc. vice president Robert Cavorsi reported multiple equity awards and a related tax share disposition. He received stock options for 53,452 shares at an exercise price of $0.00 and now holds 53,452 derivative securities. He was also granted 93,750 shares of Class A common stock and a further 16,290 shares, bringing his direct Class A holdings to 276,115 shares after all transactions.
The awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, and options that become exercisable on the same schedule. Some shares were issued from a 2025 performance share award tied to performance milestones. A total of 5,432 shares were withheld and disposed at $3.84 per share to cover tax obligations.
Organogenesis Holdings Inc. reported that Chief Financial Officer Francisco David received equity awards and had shares withheld for taxes. He was granted a stock option for 111,358 shares with no exercise cost shown here, vesting in equal annual installments over four years beginning February 15, 2026. He also received 195,312 restricted stock units, each convertible into one share of Class A common stock as they vest annually over four years starting on the same date. In addition, 43,602 shares of Class A common stock were issued upon vesting of a 2025 performance share award tied to performance milestones, and 14,541 shares were disposed of at $3.84 per share to cover tax obligations. Following these transactions, he directly owned 731,020 Class A shares.
Organogenesis Holdings Inc. reported that Chief Commercial Officer Brian Grow received new equity awards and had shares withheld for taxes. He was granted a stock option for 133,630 shares with no exercise price shown here; the option vests in equal annual installments over four years beginning February 15, 2026.
Grow also acquired 234,375 shares and 48,330 shares of Class A common stock as equity awards, tied to restricted stock units and a performance share award that vest over time based on service and performance. In connection with the vesting of the performance award, 11,768 shares were disposed of at $3.84 per share to satisfy tax withholding obligations, leaving him with 899,355 shares of Class A common stock held directly.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions. He received a stock option covering 120,267 shares of Class A common stock and was granted or issued a total of 259,549 Class A shares through stock awards on February 18, 2026.
The equity awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, as well as shares issued from a 2025 performance share award based on achievement of performance milestones. In a separate transaction, 16,212 shares were disposed of at $3.84 per share to cover tax obligations tied to these awards.
Organogenesis Holdings Inc. reported that President and CEO Gary S. Gillheeney received equity awards and related share settlements. He was granted 890,625 restricted stock units that vest in equal annual installments over four years beginning February 15, 2026. He also received 186,968 shares of Class A common stock upon vesting and settlement of a 2025 performance share award tied to performance milestones. To cover tax obligations, 90,398 shares were disposed of at $3.84 per share. In addition, he was granted stock options for 507,795 shares, which become exercisable in equal annual installments over four years beginning February 15, 2026, bringing his directly held Class A shares to 4,231,112 and option holdings to 507,795.